Arvinas' ARV-806 Demonstrates Strong Preclinical Tumor Inhibition in KRAS G12D Cancer Models

Arvinas' ARV-806 shows preclinical tumor inhibition in KRAS G12D cancer models. The company uses its PROTAC Discovery Engine platform to develop proteolysis targeting chimeras that selectively degrade disease-causing proteins. Arvinas has four clinical-stage programs, including vepdegestrant for ER+/HER2- breast cancer, ARV-766 and bavdegalutamide for metastatic castration-resistant prostate cancer, and ARV-102 for neurodegenerative disorders.